CICC published a research report stating that it essentially maintains its forecast for REMEGEN (09995)'s net losses attributable to parent company for 2025 and 2026 at RMB 915 million and RMB 333 million respectively. Due to positive Phase III clinical results for Telitacicept in Sjögren's syndrome, which is expected to enhance Telitacicept's future value proposition, and RC148's approved Phase II clinical trial in the US, which is expected to boost its overseas potential and global value space, the firm maintains its "Outperform" rating on the company while raising the target price by 24.8% to HK$95.34.

REMEGEN recently announced that it will submit a marketing application for its self-developed BLyS/APRIL dual-target fusion protein innovative drug Telitacicept to China's National Medical Products Administration Center for Drug Evaluation (CDE) as soon as possible, and will release detailed data at major international academic conferences. Additionally, the company's RC148 received FDA approval to conduct Phase II clinical studies in the US for various advanced malignant solid tumors, marking RC148's entry into the global clinical development stage and laying the foundation for advancing the product's subsequent development. The research firm believes RC148 has international clinical value and overseas potential.